N6-methyladenosine and intervertebral disc degeneration: Advances in detection and pathological insights
- PMID: 40529901
- PMCID: PMC12173039
- DOI: 10.1016/j.jot.2025.05.004
N6-methyladenosine and intervertebral disc degeneration: Advances in detection and pathological insights
Abstract
Intervertebral disc (IVD) degeneration (IDD) is a progressive condition characterized by the deterioration of the intervertebral discs, which serve as cushions between the vertebrae in the spinal column. This degeneration is often associated with aging and can be influenced by various factors, including genetics, mechanical stress, and lifestyle choices. N6-methyladenosine (m6A) modification has emerged as a critical post-transcriptional regulatory mechanism that influences various biological processes, including cellular differentiation, proliferation, and response to stress. Recent studies suggest that m6A modification play significant roles in the pathophysiology of IDD. The dysregulation of m6A methylation is linked to the altered expression of genes involved in inflammation, oxidative stress, extracellular matrix remodeling, regulated cell death including apoptosis, autophagy, pyroptosis and ferroptosis, all of which contribute to the IDD. In this review, we summarize the advanced detection technology of m6A and the roles of m6A in pathological process of IDD, to provide new insights into the molecular mechanisms underlying IDD and identify novel therapeutic targets for intervention.
The translational potential of this article: This work underscores the diagnostic and therapeutic potential of targeting m6A mechanism in IDD. Clinically, m6A regulators may serve as biomarkers for early IDD detection or progression monitoring. Therapeutically, small-molecule modulators of m6A writers/erasers or RNA-based strategies could restore ECM homeostasis, mitigate inflammation, and prevent IVD cell death. Furthermore, advanced m6A mapping technologies may enable personalized interventions by decoding patient-specific epitranscriptomic profiles. These insights bridge molecular mechanisms to clinical innovation, offering novel avenues for IDD treatment and regenerative therapies.
Keywords: Cellular metabolism; Extracellular matrix metabolism; Intervertebral disc degeneration; Oxidative stress; Regulated cell death; m6A modification.
© 2025 The Authors.
Conflict of interest statement
The authors declare that they have no competing interest.
Figures







Similar articles
-
CXCL14 drives age-related intervertebral disc degeneration via NF-κB pathway activation in a multiomic study.Sci Rep. 2025 Jul 13;15(1):25307. doi: 10.1038/s41598-025-10998-9. Sci Rep. 2025. PMID: 40653514 Free PMC article.
-
Chronotherapy and intervertebral disc degeneration: understanding the role of circadian rhythm in degenerative processes.Front Cell Dev Biol. 2025 Jun 3;13:1586193. doi: 10.3389/fcell.2025.1586193. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40530333 Free PMC article. Review.
-
METTL3 Promotes Nucleus Pulposus Cell Senescence in Intervertebral Disc Degeneration by Regulating TLR2 m6A Methylation and Gut Microbiota.J Gerontol A Biol Sci Med Sci. 2024 Aug 1;79(8):glae150. doi: 10.1093/gerona/glae150. J Gerontol A Biol Sci Med Sci. 2024. PMID: 38853707
-
Oxidative stress activates YAP/TEAD1/NCOA4 axis to promote ferroptosis of endplate chondrocytes and aggravate intervertebral disc degeneration.J Orthop Translat. 2025 Jul 12;54:8-25. doi: 10.1016/j.jot.2025.07.001. eCollection 2025 Sep. J Orthop Translat. 2025. PMID: 40688343 Free PMC article.
-
Sirtuins in intervertebral disc degeneration: current understanding.Mol Med. 2024 Mar 29;30(1):44. doi: 10.1186/s10020-024-00811-0. Mol Med. 2024. PMID: 38553713 Free PMC article.
References
-
- Martin B.I., Deyo R.A., Mirza S.K., Turner J.A., Comstock B.A., Hollingworth W., et al. Expenditures and health status among adults with back and neck problems. JAMA, J Am Med Assoc. 2008;299(6):656–664. - PubMed
-
- Jin Z., Wang D., Zhang H., Liang J., Feng X., Zhao J., et al. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis. 2020;79(8):1014–1022. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials